Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The BLESS randomized controlled trial

JAMA

Volumn 309, Issue 12, 2013, Pages 1260-1267

  Serisier, David J ^a,b,d   Martin, Megan L ^a   McGuckin, Michael A ^b   Lourie, Rohan ^b,c   Chen, Alice C ^b   Brain, Barbara ^c   Biga, Sally ^c   Schlebusch, Sanmarić ^c   Dash, Peter ^c   Bowler, Simon D ^a,b,d  

^a MATER ADULT HOSPITAL   (Australia)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^c MATER HOSPITAL   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BROMHEXINE; C REACTIVE PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLISTIN; CORTICOSTEROID; ERYTHROMYCIN ETHYLSUCCINATE; LONG ACTING DRUG; MANNITOL; PLACEBO; PREDNISOLONE; SHORT ACTING DRUG; ANTIINFECTIVE AGENT; ERYTHROMYCIN;

ACRODYNIA; ADULT; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASTHMA; AUSTRALIA; BRONCHIECTASIS; BRONCHODILATATION; CEREBROVASCULAR DISEASE; COLORECTAL CARCINOMA; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATION; FORCED EXPIRATORY VOLUME; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; LONG TERM CARE; LOW DRUG DOSE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NON CYSTIC FIBROSIS BRONCHIECTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QT PROLONGATION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINUSITIS; SPUTUM ANALYSIS; STREPTOCOCCUS; AGED; ANTIBIOTIC RESISTANCE; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; LUNG; MICROBIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; RESPIRATORY TRACT INFECTION; SPUTUM; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SPUTUM; STREPTOCOCCUS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84875543900     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.2290     Document Type: Article

References (32)

1. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in noncystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657-665.
2. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev. 2007;13(2):CD001392.
3. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162(2 pt 1):481-485. (Pubitemid 30647187)
4. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005;60(3):239-243. (Pubitemid 40380285)
5. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase 1: rhDNase Study Group. Chest. 1998;113(5):1329-1334. (Pubitemid 28223825)
6. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660-667.
7. Wilson R, Wells AU. Azithromycin in bronchiectasis: when should it be used? Lancet. 2012;380(9842):627-629.
8. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157(6 pt 1):1829-1832.
9. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007;369(9560):482-490. (Pubitemid 46209315)
10. Kastner U, Guggenbichler JP. Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. Infection. 2001;29(5):251-256. (Pubitemid 32929629)
11. Barkai G, Greenberg D, Givon-Lavi N, Dreifuss E, Vardy D, Dagan R. Community prescribing and resistant Streptococcus pneumoniae. Emerg Infect Dis. 2005;11(6):829-837. (Pubitemid 40720842)
12. Dias R, Caniça M. Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14. J Antimicrob Chemother. 2004;54(6):1035-1039. (Pubitemid 40136737)
13. Karlowsky JA, Lagacé-Wiens PR, Low DE, Zhanel GG. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. Int J Antimicrob Agents. 2009;34(4):375-379.
14. E mycin tablets 400 mg 25. HomePharmacy. http://www.homepharmacy.com.au/ products/products-list.cfm?keywords=e%20mycin. Accessed February 8, 2013.
15. Zithromax. HomePharmacy. http://www.homepharmacy.com.au/products/ products-list.cfm?keywords=zithromax. Accessed February 8, 2013.
16. Tsang KW, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J. 1999;13(2):361-364. (Pubitemid 29086834)
17. Serisier DJ, Martin ML. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med. 2011;105(6):946-949.
18. Matthews JNS, Altman DG. Interaction 3: How to examine heterogeneity. BMJ . 1996;313(7061):862. (Pubitemid 26335214)
19. Seemungal TAR, Wilkinson TMA, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associatedwith decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139-1147.
20. Albert RK, Connett J, Bailey WC, et al; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-698.
21. Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26(19):2007-2012. (Pubitemid 41435722)
22. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351(11):1089-1096.
23. Swanson DJ, Sung RJ, Fine MJ, Orloff JJ, Chu SY, Yu VL. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med. 1992;92(1):61-68.
24. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir Med . 2007;101(8):1633-1638. (Pubitemid 46930715)
25. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132(5):1565-1572. (Pubitemid 350156014)
26. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009;34(4):843-849.
27. Hyde TB, Gay K, Stephens DS, et al Active Bacterial Core Surveillance/Emerging Infections Program Network. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 2001;286(15):1857-1862. (Pubitemid 33010237)
28. Crokaert F, Hubloux A, Cauchie P. A phase I determination of azithromycin in plasma during a 6-week period in normal volunteers after a standard dose of 500 mg once daily for 3 days. Clin Drug Investig. 1998;16(2):161-166. (Pubitemid 28430060)
29. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23(3):590-615.
30. Tsang KW, Ng P, Ho PL, et al. Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro. Eur Respir J. 2003;21(3):401-406. (Pubitemid 36336196)
31. Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med . 2003;168(5):581-587. (Pubitemid 37088602)
32. Kohri K, Ueki IF, Nadel JA. Neutrophil elastase induces mucin production by ligand-dependent epidermal growth factor receptor activation. Am J Physiol Lung Cell Mol Physiol. 2002;283(3):L531-L540.